BLRD Research Career Scientist Award Application

此应用程序是一个研究职业科学家奖博士. （提名人），他是詹姆斯A。佛罗里达州坦帕的Haley VA医院和 弗吉尼亚大学附属学术中心副教授，南佛罗里达大学。以来 2007年，被提名人通过培训为退伍军人事务部的研究和服务做出了重大贡献， 与VA调查人员的指导和合作。她在国内和国际上都得到了认可 她对肿瘤生物学领域的贡献，特别是关于肿瘤的机制， 基质相互作用、基于3D培养的抗癌药物发现和纳米级抗癌药物 交付方法。她对科学文献做出了重大贡献，包括61多篇 出版物，产生了约2419次引用，累计H指数为28，i10指数为10。 为45.他还拥有12项美国专利。莫哈帕特拉博士接受了大量的校外研究 支持（约1300万美元），包括NIH，ONR，退伍军人事务部和 佛罗里达卫生部。她还担任《药物输送杂志》的客座编辑， 《转化研究》（控释学会的一份杂志）题为“纳米生物”的特刊 接口：从实验室到诊所。她被佛罗里达高科技学院选为“技术面孔” 走廊，并被授予2014年卓越创新奖由USF研究办公室 创新添Mohapatra博士获得了两项优异奖。她发起了 第三个项目是未来的优异奖提案。VA Merit Review支持的当前研究活动 (VMR)总结如下。 VMR项目#1（2016-2019）。研究新型组合治疗药物的潜力 在中度TBI的大鼠模型中的方法，其包括（i）减少炎症（局部）的治疗 和全身性）使用针对最近发现的靶标CCL 20的纳米配制的siRNA，和（ii） 通过间充质干细胞（MSC）疗法促进神经再生的第二治疗。 VMR项目#2（2017-2021）。研究新型靶向溶瘤病毒细胞的潜力 使用被普通感冒病毒、呼吸道合胞病毒（RSV）感染的MSC的治疗， 癌的该项目涉及用野生型或突变型RSV感染hMSCs并在体外进行测试 使用3D类肿瘤平台，然后使用免疫活性的 肺癌同基因原位模型。此外，她还在第三个VMR项目中担任co-I 专注于RSV。 项目#3（正在开发的VMR项目）。发现和研究小说的潜力 靶向癌症干细胞（CSC）的抗癌剂用于治疗结肠直肠癌（CRC）。 该项目涉及使用3D类肿瘤平台来筛选抗癌药物， 扩增CRC-CSC，然后在CRC-CSC的小鼠模型中测试这些药剂的治疗功效。 CRC。 这些高度创新的计划结合在一起，预计将产生很大的影响。 为退伍军人和其他有需要的美国人治疗各种疾病。总之，博士。 Mohapatra将是一个非常有效的研究职业科学家创造国家的影响， 培训，指导，研究和服务在VA。

This application is for a Research Career Scientist Award for Dr. Subhra Mohapatra (nominee) who is a research microbiologist at the James A. Haley VA Hospital, Tampa, FL, and an Associate Professor at the VA-affiliated academic center, the University of South Florida. Since 2007, the nominee has been contributing significantly to VA research and services via training, mentoring and collaboration with VA investigators. She is recognized nationally and internationally for her contributions to the field of tumor biology, particularly pertaining to mechanism of tumor- stroma interactions, 3D culture-based anti-cancer drug discovery, and nanoscale anti-cancer drug delivery approaches. She has contributed significantly to scientific literature including over 61 publications, which have generated ~2419 citations and a cumulative H-Index of 28 and i10-Index of 45. She also holds 12 US patents. Dr. Mohapatra has received substantial extramural research support (~$13 million) including awards from the NIH, ONR, Department of Veterans Affairs and Florida Department of Health. She also served as guest editor of the Journal of Drug Delivery and Translational Research (a journal of the Controlled Release Society) special issue entitled “NanoBio Interface: From Lab to Clinic.” She was selected for “Faces of Technology” by the Florida High Tech Corridor and was awarded the 2014 Excellence in Innovation award by the USF Office of Research and Innovation. Dr. Mohapatra has been funded with the two Merit Review Awards. She has initiated a third project for a future Merit proposal. Current research activities supported by VA Merit Review (VMR) are summarized below. VMR Project #1 (2016-2019). Investigate the potential of a novel combinatorial therapeutic approach in a rat model of moderate TBI that includes (i) a treatment to reduce inflammation (local and systemic) using a nano-formulated siRNA against a recently discovered target, CCL20, and (ii) a second treatment to promote neuroregeneration by mesenchymal stem cell (MSC) therapy. VMR Project #2 (2017-2021). Investigate the potential of a novel targeted oncolytic viro-cell therapy using MSCs infected by a common cold virus, respiratory syncytial virus (RSV), for lung cancers. The project involves infecting hMSCs with wild type or mutant RSV and testing them in vitro using 3D tumoroid platform and then testing their anti-cancer potential using immunocompetent syngeneic orthotopic model of lung cancer. In addition, she serves as a co-I in a third VMR project that focuses on RSV. Project #3 (VMR project in development). Discover and investigate the potential of novel anticancer agents targeting cancer stem cells (CSCs) for the treatment of colorectal cancer (CRC). The project involves use of 3D tumoroid platform to screen for anticancer agents that will inhibit expansion of CRC-CSCs and then testing therapeutic efficacy of these agents in mouse model of CRCs. These highly innovative programs taken together are expected to lead to high impact therapies for diverse diseases for Veterans and other Americans in need. In summary, Dr. Mohapatra will be highly effective as a Research Career Scientist creating national impacts in training, mentoring, research and services at the VA.